Core Viewpoint - The company, Xianjian Technology (01302.HK), has received formal notification from the National Medical Products Administration confirming that its Concave Supra integrated arch branch reconstruction system (CSTM stent system) has entered the special review procedure for innovative medical devices. This product is designed for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, marking a significant advancement in the field [1]. Group 1 - The CSTM stent system is the world's first integrated arch branch reconstruction solution that does not require brain ischemia, addressing a critical need in vascular surgery and endovascular intervention [1]. - This product is the 17th to enter the special review procedure by the National Medical Products Administration, indicating the company's strong pipeline of innovative medical devices [1]. - The aortic arch region is known for its complex anatomy and unique hemodynamics, making it one of the most challenging areas in vascular surgery [1]. Group 2 - The CSTM stent system was developed in collaboration with Professor Shu Chang from the National Center for Cardiovascular Diseases and Fuwai Hospital, showcasing the company's commitment to partnerships in advancing medical technology [1]. - The system employs a unique groove and integrated structure, fundamentally addressing multiple technical challenges associated with traditional endovascular techniques in arch branch reconstruction [1]. - This innovation provides a systematic, minimally invasive, and safer solution for complex arch lesions, representing a significant leap forward in treatment options [1].

【换手率高】 -今日A股共有50只个股换手率超过30%； 【振幅大】 -今日A股共有33只个股振幅超过20%； -C陕旅、天力复合、天润科技等个股振幅居前； -C陕旅、创新医疗、御银股份等个股换手率居前； 【主力资金】 -主力资金今日净流入计算机、传媒、非银金融等板块，净流出电力设备、电子、基础化工等板块； -东方财富、领益智造、岩山科技、山子高科、海格通信资金净流入规模居前，分别净流入18.10亿元、 16.47亿元、14.10亿元、14.03亿元、11.41亿元； -阳光电源、金风科技、新易盛、乾照光电、胜宏科技资金净流出规模居前，分别净流出20.81亿元、 19.58亿元、18.40亿元、13.91亿元、13.43亿元。 ...

Group 1: Industry Overview - Brain-computer interface (BCI) technology is at a critical juncture of "technological breakthrough to commercialization," supported by policies, technology, and application scenarios [2] - The global market for BCI is expected to change due to policy benefits, external production expectations, and domestic clinical breakthroughs [2] - Invasive BCI products are still in clinical trials, while non-invasive products, such as rehabilitation systems and sleep aids, have been partially launched [2] Group 2: Technological Advancements - Advancements in chips, electrodes, and algorithms, along with improved regulatory standards, are expected to lead to intensive commercialization of BCI products in the coming years [2] - Companies like Neuralink plan to start large-scale production of BCI devices by 2026, with significant innovations in surgical procedures [2] Group 3: Competitive Landscape - The BCI industry in China is still in its early stages, with most companies being small in scale [2] - There is a notable advantage in the signal quality of invasive BCIs, while non-invasive BCIs offer high safety and ease of operation, serving as a complement to invasive types [2] Group 4: Industry Chain and Key Players - Upstream: Innovative Medical has strategically invested in Hangzhou Boling Medical Technology to enter the BCI field [3] - Midstream: Nanjing Panda is developing key technologies for multimodal human-computer interaction systems based on BCI technology [6] - Downstream: Sanbo Neuroscience has achieved breakthroughs in precise tumor removal technology and is exploring clinical applications related to brain science [8]

Core Viewpoint - The article emphasizes the importance of bridging the technology chain and completing the talent chain to promote the application of brain-computer interface (BCI) technology, highlighting the achievements of Tianjin University's Brain-Computer Interaction and Human-Machine Integration Haihe Laboratory in this field [1] Group 1: Technological Advancements - The Tianjin University team focuses on non-invasive brain-computer interfaces, driving technological innovation and industrial application [1] - A comprehensive layout has been established, covering high-performance devices, chips, algorithms, platforms, system integration, and key applications [1] Group 2: Clinical Applications - The "Shengong" brain-computer interaction medical device series has been developed, addressing clinical applications such as stroke rehabilitation, spinal cord injury assistance, depression treatment, and auditory disorders [1] Group 3: Aerospace Applications - The laboratory has designed and developed the fifth-generation space station on-orbit brain-computer interaction system, achieving the first human "space brain-computer interface experiment" [1] - Significant applications have been realized in subsequent manned flight missions, enhancing astronauts' functional and emotional state detection, providing critical technical support for China's manned space engineering [1]

脑机接口概念持续走强，南京熊猫6天5板，道氏技术"20cm"涨停，创新医疗、诚益通、三博脑科、翔 宇医疗、美好医疗、伟思医疗跟涨。 脑机接口概念持续走强，南京熊猫6天5板，道氏技术"20cm"涨停，创新医疗、诚益通、三博脑科、翔 宇医疗、美好医疗、伟思医疗跟涨。 ...

Group 1 - The A-share market saw a strong performance in brain-computer interface concept stocks, with several companies approaching or hitting their daily limit up [1] - Notable gainers included Entropy Technology, which approached a 20% limit up, and Dao's Technology and Yingkang Life, both rising over 13% [1] - Other significant performers included Tom Cat, which increased by over 10%, and Yanshan Technology, which hit a 10% limit up [1] Group 2 - The table lists various companies with their respective stock codes, percentage increase, total market capitalization, and year-to-date performance [2] - Entropy Technology (301330) had a 19.40% increase, with a market cap of 11.7 billion and a year-to-date increase of 50.11% [2] - Dao's Technology (300409) rose by 13.91%, with a market cap of 25.9 billion and a year-to-date increase of 47.49% [2] - Yingkang Life (300143) increased by 13.01%, with a market cap of 10 billion and a year-to-date increase of 35.43% [2] - Other companies like Tom Cat (300459) and Yanshan Technology (002195) also showed significant gains, with year-to-date increases of 29.63% and 60.65% respectively [2]

Core Viewpoint - The A-share market has seen a strong performance in brain-computer interface concept stocks, with several companies approaching or hitting their daily price limits [1] Group 1: Stock Performance - Entropy Technology (熵基科技) approached a 20% daily limit increase, with a rise of 19.40% and a market capitalization of 11.7 billion [2] - Dao's Technology (道氏技术) increased by 13.91%, reaching a market cap of 25.9 billion [2] - Yingkang Life (盈康生命) rose by 13.01%, with a market cap of 10 billion [2] - Tom Cat (汤姆猫) saw a 10.19% increase, with a market cap of 20.9 billion [2] - Rock Mountain Technology (岩山科技) hit a 10% daily limit increase, with a market cap of 64.6 billion [2] - Three Seven Entertainment (三七互娱) approached a 10% daily limit increase, with a rise of 9.97% and a market cap of 66.4 billion [2] - Other notable performers include Aipeng Medical (爱朋医疗) at 9.99%, Lens Technology (蓝思科技) at 9.80%, and Nanjing Panda (南京熊猫) at 9.33% [2] Group 2: Year-to-Date Performance - Entropy Technology has a year-to-date increase of 50.11% [2] - Dao's Technology has risen 47.49% year-to-date [2] - Yingkang Life has a year-to-date increase of 35.43% [2] - Tom Cat has increased by 29.63% year-to-date [2] - Rock Mountain Technology has a significant year-to-date increase of 60.65% [2] - Aipeng Medical has a year-to-date increase of 54.31% [2] - Nanjing Panda has a remarkable year-to-date increase of 63.01% [2] - Other companies like Innovation Medical (创新医疗) and Keda Xunfei (科大讯飞) have year-to-date increases of 74.01% and 19.29%, respectively [2]

Investment Rating - The report maintains a positive investment rating for the brain-computer interface (BCI) industry, highlighting significant investment opportunities expected in 2026 [2]. Core Insights - The brain-computer interface industry is entering a golden period of development, with a broad blue ocean market. Global strategic layouts are being actively pursued by the US, EU, Japan, and other regions, leading to a growing number of companies and active investment activities [1]. - The BCI technology is at a critical stage of transitioning from technological breakthroughs to practical applications, with the market expected to grow significantly over the next decade. The global BCI market is projected to reach approximately $2.94 billion by 2025 and grow to about $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% from 2025 to 2034 [6][20]. - The report emphasizes the importance of policy support and technological advancements in driving the growth of the BCI industry, with significant investments and initiatives from various governments [20][30]. Industry Overview - The BCI technology has evolved through three stages: the initial stage (1.0), the development stage (2.0), and the current intelligent and integrated stage (3.0) [20]. - The BCI market is characterized by diverse applications, with at least 30 identified use cases across medical, consumer, and industrial sectors. Medical applications currently dominate, accounting for 56% of the industry, while non-medical applications are rapidly expanding [18][19]. Market Size and Growth - The BCI market is expected to experience accelerated growth in the next decade, driven by the increasing adoption of BCI technologies across various sectors. The report forecasts a significant rise in market size, with a focus on the rapid development of non-invasive BCI technologies [6][20]. - The report highlights that the US and China are leading the global BCI technology and industry development, with major companies like Neuralink and Qiang Brain Technology making significant advancements [6][20]. Investment Recommendations - The report recommends focusing on companies involved in BCI technology, particularly those with strong market positions such as Dao Technology (which has a stake in Qiang Brain Technology) and other related firms in the flexible sensor sector [6][20]. - It also suggests monitoring developments in the medical device sector related to BCI technologies, emphasizing the importance of medical-grade BCI products [6][20].

Core Insights - The commercialization of brain-computer interfaces (BCIs) is steadily advancing, presenting vast market opportunities in China, where competition is still in its early stages with most companies being small and not yet in a saturated market [1] - Invasive BCIs have significant advantages in signal quality, while non-invasive BCIs offer high safety and ease of use, serving as a complement to invasive types [1] - The current focus of the industry is on the medical field, with potential future expansion into non-medical areas [1] Group 1: Global Developments - Neuralink, a global leader in BCIs, is expected to enter the commercialization phase by 2026, with 12 patients having successfully implanted devices as of September 2025 [2] - Neuralink plans to increase the number of electrodes in its devices to over 30,000 by 2028, aiming for comprehensive brain connectivity [2] - The company has outlined three core product lines: Telepathy for motor disabilities, Blindsight for visual impairments, and Deep for neurological disorders [2] Group 2: Competitive Barriers - Key competitive advantages for Neuralink include flexible electrode arrays, precise implantation robots, and low-power intracranial signal processing systems [3] - The development of a closed-loop technical system through interdisciplinary research and clinical collaboration is essential for domestic companies [3] Group 3: Industry Trends in China - National strategies are guiding the BCI industry, with policies expected to be released in 2025 to support development [4] - Clinical advancements are accelerating, with significant breakthroughs in invasive and semi-invasive BCI systems reported in 2025 [4] - The financing market for BCIs is thriving, with 24 financing events recorded in 2025, marking a 30% increase year-on-year [4] - The supporting industrial chain for BCIs is rapidly forming, with pilot implementations in medical and everyday scenarios [4]

| 序号 | | | | | --- | --- | --- | --- | | | 证券代码 ◆ | 证券简称 ◆ | 交易日期⇒ | | 1 | 601318.SH | 中国部安 | 2026-01-09 | | 2 | 002202.SZ | 金风科技 | 2026-01-09 | | ന | 300308.SZ | 中际旭创 | 2026-01-09 | | ব | 300418.SZ | 昆仑万维 | 2026-01-09 | | 5 | 600030.SH | 中信证券 | 2026-01-09 | | 6 | 300136.SZ | 信维通信 | 2026-01-09 | | 7 | 300450.SZ | 先导智能 | 2026-01-09 | | 8 | 002173.SZ | 创新医疗 | 2026-01-09 | | ರಿ | 603179.SH | 新泉股份 | 2026-01-09 | | 10 | 300750.SZ | 宁德时代 | 2026-01-09 | 中泰证券研报表示，中国商业航天正从"探索验证"阶段向"成长爆发"期过渡，行业迎来关键发展拐点。预计在"十五五"期间，随着政 ...